Analysts' Actions: DLB, GGP, MLM, ORCL

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Accretive Health(AH) was downgraded to Sell at TheStreet Ratings.

Dolby(DLB) was downgraded at JP Morgan from Overweight to Neutral. Company lacks near-term catalysts, JP Morgan said. $48 price target.

Extra Space Storage(EXR) was downgraded at Jefferies to Hold from Buy. Valuation hard to ignore, Jefferies said.

General Growth(GGP) was upgraded at UBS to Buy from Neutral. $20 price target. Estimates were also increased on multiple near-term catalysts, UBS said.

Human Genome(HGSI) was downgraded at Leerink Swann to Market Perform. See little upside potential to Glaxo's hostile bid, Leerink Swann said.

Highwood Properties(HIW) was downgraded at Jefferies to Hold from Buy. $36 price target. Valuation now reflects fundamentals, Jefferies said.

Harsco(HSC) was upgraded at Keybanc from Hold to Buy. $27 price target. Management change should improve shareholder value, Keybanc said.

Martin Marietta(MLM) was downgraded at RBC Capital to Sector Perform. Valuation call, based on a $99 price target, RBC Capital said.

3M(MMM) was downgraded at Bernstein from Outperform to Market Perform. $101 price target. Company is trying to balance between growth and margins, Bernstein said.

Vail Resorts(MTN) was downgraded at Wells Fargo from Outperform to Market Perform. Company lacks near-term catalysts, Wells Fargo said.

Oracle(ORCL) was downgraded at ThinkEquity from Buy to Hold. $28 price target. New analyst believes that the company lacks near-term catalysts, ThinkEquity said.

Pros Holdings(PRO) was downgraded to Hold at TheStreet Ratings.

Prudential(PRU) was upgraded at Credit Suisse from Equal-Weight to Overweight. Valuation call, based on a $66 price target, Credit Suisse said.

Teva Pharmaceutical(TEVA) was downgraded at Needham from Strong Buy to Hold. Company is posting lower sales and withdrew its guidance, Needham said.

Marriott Vacations(VAC) was upgraded at Goldman Sachs from Neutral to Buy. Valuation call, based on a $38 price target, Goldman Sachs said.

STOCK COMMENTS / EPS CHANGES

BMC Software(BMC) price target was raised at Jefferies to $48. Operational improvements place company in a better position, Jefferies said.